Late filing
elevated
Filing comparison
Keenova Therapeutics plc filed its annual report late and said it expects a significant change in results
expects significant change in results 1 day past the statutory due date.
Keenova Therapeutics plc (the “Company”) is unable to file, without unreasonable effort or expense, its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 (the “Form 10‑K”), with the Securities and Exchange Commission (the “SEC”) within the prescribed time period. The Company requires additional time to complete certain analyses and disclosures to be included in the Form 10-K due to the complexity of the accounting related to (i) the Company’s business combination with Endo, Inc. (“Endo”) completed in July 2025 (the “Business Combination”) and (ii) the Company’s separation of its generic pharmaceuticals and sterile injectables businesses into an independent, private…
Evidence
- Anticipates significant change
- Yes
- Days past due date
- 1
- Other periodic reports filed
- Yes
- Routine
- No
- Severity
- elevated
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- Keenova Therapeutics plc (the “Company”) is unable to file, without unreasonable effort or expense, its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 (the “Form 10‑K”), with the Securities and Exchange Commission (the “SEC”) within the prescribed time period. The Company requires additional time to complete certain analyses and disclosures to be included in the Form 10-K due to the complexity of the accounting related to (i) the Company’s business combination with Endo, Inc. (“Endo”) completed in July 2025 (the “Business Combination”) and (ii) the Company’s separation of its generic pharmaceuticals and sterile injectables businesses into an independent, private…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.